Cardiology · 2026
Aortic Valve Calcification Scores versus CT-FFR: Prediction of Major Adverse Cardiovascular Events after Transcatheter Aortic Valve Replacement.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Li Shuangxin, Wang Xugang, Yang Wenxuan, Liu Jiali, Zheng Ruoshui, Shu Jun, Bai Yongkang, Yang Jian, Zheng Minwen, Wen Didi
Аннотация
INTRODUCTION: This study aimed to assess the prognostic value of aortic valve calcification (AVC) score and CT angiography-derived fractional flow reserve (CT-FFR) for major adverse cardiovascular events (MACEs) after transcatheter aortic valve replacement (TAVR).
METHODS: In this retrospective observational cohort study, we included patients with severe aortic valve diseases undergoing TAVR between February 2016 and April 2022. Patients were followed, and univariable and multivariate Cox regression were applied for outcome analysis using a composite endpoint including all-cause mortality, nonfatal myocardial infarction, unstable angina, heart failure rehospitalization. The incremental prognostic value of CT-FFR was also analyzed.
RESULTS: A total of 251 patients were enrolled (mean age, 67 ± 10 years; 176 men). During a mean follow-up period of 36 months, 60 (23.9%) patients experienced MACE. AVC score ≥2,000 (hazard ratio [HR] = 1.714, 95% confidence intervals [CI]: 1.020, 2.882, p = 0.042) and CT-FFR ≤0.8 (HR = 3.248, 95% CI: 1.760, 5.996, p < 0.001) were independent predictors of MACE. The C statistics revealed that adding CT-FFR to the clinical risk factors alone or combined with AVC score provided incremental prognostic value for MACE after TAVR (C-index: 0.697 vs. 0.645 [p = 0.012]; and 0.710 vs. 0.672 [p = 0.030]).
CONCLUSION: AVC score and CT-FFR were associated with MACE in patients after TAVR, and CT-FFR presented incremental prognostic value for MACE beyond clinical risk factors alone or combined with AVC score. Therefore, CT-FFR may provide incremental prognostic information and requires prospective validation prior to routine implementation.
METHODS: In this retrospective observational cohort study, we included patients with severe aortic valve diseases undergoing TAVR between February 2016 and April 2022. Patients were followed, and univariable and multivariate Cox regression were applied for outcome analysis using a composite endpoint including all-cause mortality, nonfatal myocardial infarction, unstable angina, heart failure rehospitalization. The incremental prognostic value of CT-FFR was also analyzed.
RESULTS: A total of 251 patients were enrolled (mean age, 67 ± 10 years; 176 men). During a mean follow-up period of 36 months, 60 (23.9%) patients experienced MACE. AVC score ≥2,000 (hazard ratio [HR] = 1.714, 95% confidence intervals [CI]: 1.020, 2.882, p = 0.042) and CT-FFR ≤0.8 (HR = 3.248, 95% CI: 1.760, 5.996, p < 0.001) were independent predictors of MACE. The C statistics revealed that adding CT-FFR to the clinical risk factors alone or combined with AVC score provided incremental prognostic value for MACE after TAVR (C-index: 0.697 vs. 0.645 [p = 0.012]; and 0.710 vs. 0.672 [p = 0.030]).
CONCLUSION: AVC score and CT-FFR were associated with MACE in patients after TAVR, and CT-FFR presented incremental prognostic value for MACE beyond clinical risk factors alone or combined with AVC score. Therefore, CT-FFR may provide incremental prognostic information and requires prospective validation prior to routine implementation.